EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Early defibrotide therapy and risk factors for post‐transplant veno‐occlusive disease/sinusoidal obstruction syndrome in childhood

Hironori Goto iD, Utako Oba, Tamaki Ueda iD, Shunsuke Yamamoto iD, Masataka Inoue, Yu Shimo, Satomi Yokoyama, Yusuke Takase iD, Wakako Kato iD, Souichi Suenobu iD, Kenji Ihara iD, Yuhki Koga und 1 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Hironori Goto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Hepatic Veno-Occlusive Disease, Polydeoxyribonucleotides, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Veno‐occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life‐threatening complications of hematopoietic cell transplantation (HCT).

Methods

We studied the impact of early defibrotide (DF) therapy on the outcomes of pediatric patients with VOD/SOS after transplantation, focusing on recent immunotherapies. A total of 111 pediatric patients who underwent HCT for malignant disease between February 2017 and March 2023 at Kyushu University Hospital were included.

Results

Among 111 patients of less than 20 years of age who underwent HCT for malignancy at a single institution between 2017 and 2023, VOD/SOS occurred in 25 (23%) patients. VOD/SOS developed more frequently in the post‐DF era (2020–2023, n = 58) than in the pre‐DF era (31% vs. 13%, p = .04). The proportion of patients with relapsed/refractory acute lymphoblastic leukemia (ALL) was higher in the post‐DF era than in the pre‐DF era (44% vs. 8%, p = .04). Early DF therapy that was started at two European Society for Blood and Marrow Transplantation diagnostic criteria reduced the severity of VOD/SOS ( p < .01) in comparison to non‐early therapy started at less than two criteria. A multivariate analysis indicated that a history of cytokine release syndrome (odds ratio [OR] = 10.4, p = .01) and juvenile myelomonocytic leukemia (OR = 8.98, p = .04), but not an endothelial activation and stress index (EASIX) score of greater than 0.85, were independent risk factors for VOD/SOS.

Conclusions

Early DF therapy improves the severity and survival outcomes of post‐transplant VOD/SOS in children. However, its incidence is increasing in the era of immunotherapy for progressive diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic Veno-Occlusive DiseasePolydeoxyribonucleotidesHematopoietic Stem Cell TransplantationHumansMaleChildFemaleChild, PreschoolAdolescentRisk FactorsInfantRetrospective StudiesFollow-Up StudiesFibrinolytic AgentsPrognosisSurvival RateYoung AdultAdult

Stichwörter der Autor:innen

VOD/SOScytokine release syndromedefibrotideimmunotherapy

Substanzen

defibrotidePolydeoxyribonucleotidesFibrinolytic Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Pediatrics, Oita University Faculty of Medicine, Oita, Japan.
  • Department of Pediatrics, NHO Kumamoto Medical Center, Kumamoto, Japan.
  • Department of Pediatrics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
  • National Hospital Organization Nishibeppu National Hospital, Oita, Japan.
  • Department of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.

ORCID-Profile: Hironori Goto, Tamaki Ueda, Shunsuke Yamamoto, Yusuke Takase, Wakako Kato, Souichi Suenobu, Kenji Ihara

Zitieren

APA

Goto, H., Oba, U., Ueda, T., Yamamoto, S., Inoue, M., Shimo, Y., Yokoyama, S., Takase, Y., Kato, W., Suenobu, S., Ihara, K., Koga, Y., & Ohga, S. (2024). Early defibrotide therapy and risk factors for post‐transplant veno‐occlusive disease/sinusoidal obstruction syndrome in childhood. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31331

Vancouver

Goto H, Oba U, Ueda T, Yamamoto S, Inoue M, Shimo Y, et al. Early defibrotide therapy and risk factors for post‐transplant veno‐occlusive disease/sinusoidal obstruction syndrome in childhood. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31331

BibTeX
@article{Goto2024,
  author = {Goto, Hironori and Oba, Utako and Ueda, Tamaki and Yamamoto, Shunsuke and Inoue, Masataka and Shimo, Yu and Yokoyama, Satomi and Takase, Yusuke and Kato, Wakako and Suenobu, Souichi and Ihara, Kenji and Koga, Yuhki and Ohga, Shouichi},
  title = {Early defibrotide therapy and risk factors for post‐transplant veno‐occlusive disease/sinusoidal obstruction syndrome in childhood},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31331}
}
Kostenlos starten →